Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5086174 | 1.00 | F10 (1.00) | F10 | |
| SCHEMBL5094529 | 0.85 | F10 (1.00) | F10 | |
| SCHEMBL5202069 | 0.82 | F10 (1.00) | F10 | |
| SCHEMBL5088115 | 0.77 | F10 (1.00) | F10 | |
| SCHEMBL6066660 | 0.75 | F10 (1.00) | F10 | |
| SCHEMBL6066746 | 0.75 | F10 (0.75) | F10 | |
| SCHEMBL5089014 | 0.75 | F10 (0.80) | F10 | |
| SCHEMBL6066418 | 0.74 | F10 (0.85) | F10 | |
| SCHEMBL6066395 | 0.74 | F10 (0.81) | F10 | |
| SCHEMBL6066452 | 0.73 | F10 (1.00) | F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7435747-B2 | Guanidine and amidine derivatives as factor Xa inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-10-14 | — | — | US | disclosed |
| US-7435747-B2 | Guanidine and amidine derivatives as factor Xa inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-10-14 | — | — | US | disclosed |
| US-7435747-B2 | Guanidine and amidine derivatives as factor Xa inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-10-14 | — | — | US | disclosed |
| EP-1345900-B1 | GUANIDINE AND AMIDINE DERIVATIVES AS FACTOR XA INHIBITORS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2007-01-17 | — | — | EP | disclosed |
| EP-1345900-B1 | GUANIDINE AND AMIDINE DERIVATIVES AS FACTOR XA INHIBITORS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2007-01-17 | — | — | EP | disclosed |
| US-20050143419-A1 | Guanidine and amidine derivatives as factor Xa inhibitors | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-06-30 | — | — | US | disclosed |
| EP-1345900-A1 | GUANIDINE AND AMIDINE DERIVATIVES AS FACTOR XA INHIBITORS | Sanofi-Aventis Deutschland GmbH (DE) | 2003-09-24 | — | — | EP | disclosed |
| US-20020173656-A1 | Guanidine and amidine derivatives as factor Xa inhibitors | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-11-21 | — | — | US | disclosed |
| WO-2002046159-A1 | GUANIDINE AND AMIDINE DERIVATIVES AS FACTOR XA INHIBITORS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020173656-A1 | Guanidine and amidine derivatives as factor Xa inhibitors | F5, F9, F10 | F10 3/4885 |
| US-20050143419-A1 | Guanidine and amidine derivatives as factor Xa inhibitors | F5, F10, F12 | F10 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.